Abstract
Objective To explore the role of miR-483-5p in breast cancer,and investigate the expression of miR-483-5p in human normal breast skin cells (CCD-1095Sk),human breast cancer cell lines (MCF-7,MDA-MB-231),paired breast cancer tissues and adjacent non-tumor breast tissues.Methods The expression level of miR-483-5p in human normal breast skin cells (CCD-1095Sk),human breast cancer cell lines (MCF-7,MDA-MB-231),paired breast cancer tissues and adjacent non-tumor breast tissues was detected by using reverse transcription polymerase chain reaction (RT-PCR).MDA-MB-231 cells were transfected with miR-483-5p mimics and subjected to proliferation,cell cycle,apoptosis,and Transwell assays.Results The relative expression of miR-483-5p in human breast cancer specimens was 0.6333 ±0.1898,which was significantly lower than 1.4471 ±0.3908 of adjacent non-tumor breast tissues.miR-483-5p was also down-regulated in human breast cancer cell lines (MCF-7,MDA-MB-231) as compared with normal breast skin cells (CCD-1095Sk) (0.3290 ± 0.0219 and 0.2307 ± 0.0144 vs.1.0000 ±0.0000,both P < 0.05).miR-483-5p mimics-transfected cells exhibited significantly reduced cell proliferation and the proliferation rate was 65.68%.Transwell assay revealed that the amount of invaded MDA-MB-231 cells in miR-483-5p transfected groups was significantly declined as compared with the control and scramble groups (89.8 ± 12.4 vs.203.8 ± 12.0 and 199.3 ± 13.1,both P <0.05).In comparison to control group,cell cycle was arrested in G0/G1 phase [(55.1 ± 5.2) %] and there was no significant difference in apoptosis of cells transfected with miR-483-5p mimics.Conclusion miR-483-5p,which is down-regulated in human breast cancer specimens and cell lines,can suppress proliferation and invasive ability in vitro. Key words: Breast cancer; miR-483-5p; Proliferation; Invasion
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.